Firebrick to file appeal seeking immediate approval of Nasodine

  01 Mar 2022

Firebrick Pharma announced today that the Company had decided to file an appeal against TGA’s initial decision not to approve Nasodine® Nasal Spray (“Nasodine”) for sale in Australia, based on the existing clinical data. If successful, the appeal could lead to approval of Nasodine sometime in 2022. If unsuccessful, we will re-submit to TGA at…

Read More